Management of biochemical recurrence after primary treatment of prostate cancer: A systematic review of the literature

European Urology

Volumn 64, Issue 6, 2013, Pages 905-915

  Punnen, Sanoj ^a   Cooperberg, Matthew R ^a   D'Amico, Anthony V ^b   Karakiewicz, Pierre I ^c   Moul, Judd W ^d,e   Scher, Howard I ^f   Schlomm, Thorsten ^g   Freedland, Stephen J ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Department of Surgery ^*  (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Management; Prostate cancer; Recurrence

Indexed keywords

BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; BLEEDING; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CRYOABLATION; CRYOTHERAPY; CYSTITIS; DIARRHEA; GASTROINTESTINAL TOXICITY; HEMATURIA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; ILEUS; MORTALITY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RADIATION INJURY; RECTUM INJURY; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; SYSTEMATIC REVIEW; URETHRA STRICTURE; URINE INCONTINENCE;

MANAGEMENT; PROSTATE CANCER; RECURRENCE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84887402225     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.025     Document Type: Review

References (56)

1. M.M. Center, A. Jemal, and J. Lortet-Tieulent International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
2. O.W. Brawley Prostate cancer epidemiology in the United States World J Urol 30 2012 195 200
3. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
4. E. Rosenbaum, A. Partin, and M.A. Eisenberger Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations J Natl Compr Canc Netw 2 2004 249 256
5. M.N. Simmons, A.J. Stephenson, and E.A. Klein Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy Eur Urol 51 2007 1175 1184
6. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 2009 e1000100
7. M.E. Nielsen, and A.W. Partin The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer Rev Urol 9 2007 57 62
8. W.J. Ellis, R.L. Vessella, J.L. Noteboom, P.H. Lange, R.L. Wolfert, and H.G. Rittenhouse Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay Urology 50 1997 573 579
9. A.V. D'Amico, J.W. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.-H. Chen Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383
10. K.M. Kernek, M.O. Koch, J.K. Daggy, B.E. Juliar, and L. Cheng The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence J Clin Pathol 58 2005 725 728
11. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
12. M.S. Cookson, G. Aus, and A.L. Burnett Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes J Urol 177 2007 540 545
13. L. Boccon-Gibod, W.B. Djavan, and P. Hammerer Management of prostate-specific antigen relapse in prostate cancer: a European Consensus Int J Clin Pract 58 2004 382 390
14. J.D. Cox, D.J. Grignon, R.S. Kaplan, and J.T. Parsons Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel Int J Radiat Oncol Bio Phys 37 1997 1035 1041
15. M. Roach, G. Hanks, H. Thames, and P. Schellhammer Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
16. M.E. Nielsen, D.V. Makarov, E. Humphreys, L. Mangold, A.W. Partin, and P.C. Walsh Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion - "Nadir + 2?" Urology 72 2008 389 393
17. Spiess PE, Levy DA, Pisters LL, Mouraviev V, Jones JS. Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. World J Urol 2012; http://dx.doi.org/10.1007/s00345-012-0982-2.
18. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439
19. F. Abdollah, S. Boorjian, and C. Cozzarini Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification Eur Urol 64 2013 557 564
20. S.F. Shariat, P.I. Karakiewicz, C.G. Roehrborn, and M.W. Kattan An updated catalog of prostate cancer predictive tools Cancer 113 2008 3075 3099
21. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
22. P. Martino, V. Scattoni, and A.B. Galosi Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU) World J Urol 29 2011 595 605
23. E.S. Antonarakis, Z. Feng, and B.J. Trock The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up BJU Int 109 2012 32 39
24. Z.A. Dotan, F.J. Bianco, and F. Rabbani Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy J Clin Oncol 23 2005 1962 1968
25. O.T. Okotie, W.J. Aronson, and J.A. Wieder Predictors of metastatic disease in men with biochemical failure following radical prostatectomy J Urol 171 2004 2260 2264
26. A.B. Apolo, N. Pandit-Taskar, and M.J. Morris Novel tracers and their development for the imaging of metastatic prostate cancer J Nucl Med 49 2008 2031 2041
27. J.R. Osborne, N.H. Akhtar, S. Vallabhajosula, A. Anand, K. Deh, and S.T. Tagawa Prostate-specific membrane antigen-based imaging Urol Oncol 31 2013 144 154
28. M. Picchio, E. Giovannini, and C. Messa The role of PET/computed tomography scan in the management of prostate cancer Curr Opin Urol 21 2011 230 236
29. M. Picchio, A. Briganti, and S. Fanti The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer Eur Urol 59 2011 51 60
30. M. Beheshti, R. Vali, and P. Waldenberger Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study Eur J Nucl Med Mol Imaging 35 2008 1766 1774
31. A. Alfarone, V. Panebianco, and O. Schillaci Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer Crit Rev Oncol Hematol 84 2012 109 121
32. T. Tamada, T. Sone, and Y. Jo Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors AJR Am J Roentgenol 197 2011 408 414
33. S. Cirillo, M. Petracchini, and L. D'Urso Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound BJU Int 102 2008 452 458
34. W. Luboldt, R. Küfer, and N. Blumstein Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases Radiology 249 2008 1017 1025
35. E.Y. Yu, K. Miller, and J. Nelson Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer J Urol 188 2012 103 109
36. R. Choo, G. Hruby, J. Hong, E. Bahk, and E. Hong (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy Int J Radiat Oncol Biol Phys 53 2002 269 276
37. B.J. Trock, M. Han, and S.J. Freedland Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769
38. S.A. Boorjian, R.J. Karnes, P.L. Crispen, L.J. Rangel, E.J. Bergstralh, and M.L. Blute Radiation therapy after radical prostatectomy: impact on metastasis and survival J Urol 182 2009 2708 2714
39. A.J. Stephenson, P.T. Scardino, and M.W. Kattan Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041
40. C. Parker, N. Clarke, and J. Logue RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery) Clin Oncol (R Coll Radiol) 19 2007 167 171
41. C.R. King The timing of salvage radiotherapy after radical prostatectomy: a systematic review Int J Radiat Oncol Biol Phys 84 2012 104 111
42. W.U. Shipley, D. Hunt, and H.R. Lukka Initial report of RTOG 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-2, NO disease and elevated PSA levels J Clin Oncol 29 Suppl 7 2011
43. C.M. Moinpour, K.A. Hayden, and J.M. Unger Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy J Clin Oncol 26 2008 112 120
44. D. Khuntia, C.A. Reddy, A. Mahadevan, E.A. Klein, and P.A. Kupelian Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer 100 2004 1283 1292
45. A.J. Stephenson, P.T. Scardino, F.J. Bianco, and J.A. Eastham Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy Curr Treat Options Oncol 5 2004 357 365
46. D.C. Chade, J. Eastham, and M. Graefen Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature Eur Urol 61 2012 961 971
47. D.C. Chade, S.F. Shariat, and A.M. Cronin Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration Eur Urol 60 2011 205 210
48. B. Rocco, G. Cozzi, and M.G. Spinelli Current status of salvage robot-assisted laparoscopic prostatectomy for radiorecurrent prostate cancer Curr Urol Rep 13 2012 195 201
49. G.T. Gotto, L.H. Yunis, K. Vora, J.A. Eastham, P.T. Scardino, and F. Rabbani Impact of prior prostate radiation on complications after radical prostatectomy J Urol 184 2010 136 142
50. Ramey SJ, Marshall DT. Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol 2012; http://dx.doi.org/10. 1007/s00345-012-0953-7.
51. V. Mouraviev, P.E. Spiess, and J.S. Jones Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy Eur Urol 61 2012 1204 1211
52. N. Lawrentschuk, A. Finelli, and T.H. Van der Kwast Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer J Urol 185 2011 862 868
53. J. Riviere, J.-C. Bernhard, and G. Robert Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer Eur Urol 58 2010 567 573
54. S. Wenske, S. Quarrier, and A.E. Katz Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre Eur Urol 64 2013 1 7
55. S.A. Siddiqui, S.A. Boorjian, B. Inman, S. Bagniewski, E.J. Bergstralh, and M.L. Blute Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study J Urol 179 2008 1830 1837 discussion 1837
56. J.W. Moul, H. Wu, and L. Sun Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 2004 1141 1147